Please login to the form below

Not currently logged in
Email:
Password:

Pear Therapeutics

This page shows the latest Pear Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment

Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment

Pear Therapeutics is a pioneer of so-called digital therapeutics, having gained the first ever such approval from the FDA in 2017, for its treatment for patients with Substance Use Disorder ... Like a drug filing with the FDA, Pear Therapeutics is

Latest news

  • FDA clears Sandoz and Pear’s Opioid Use Disorder app FDA clears Sandoz and Pear’s Opioid Use Disorder app

    Its partnership with Pear Therapeutics reflects the growing need for pharma companies to go 'beyond the pill' and offer health systems and patients support in staying on their medication. ... Pear Therapeutics’ solution is modelled on the Community

  • Sandoz targets digital therapeutics Sandoz targets digital therapeutics

    Partners with Pear Therapeutics to launch FDA-approved apps. Novartis’ generics and biosimilar division Sandoz has partnered with Pear Therapeutics to commercialise two mobile phone applications, reSET and reSET-O. ... Corey McCann, president and chief

  • Novartis plans digital therapeutics for schizophrenia and MS Novartis plans digital therapeutics for schizophrenia and MS

    The work will see the Swiss pharma company partner with Pear Therapeutics, a leading light in the emerging digital therapeutics field. ... Novartis said its collaboration with Pear Therapeutics would see the partners work to “better address the full

  • Roche and J&J picked for ‘revolutionary’ digital health pilot Roche and J&J picked for ‘revolutionary’ digital health pilot

    Just nine firms were picked for the pilot: Apple, Fitbit, J&J, Pear Therapeutics, Phosphorus, Roche, Samsung, Tidepool and Verily.

  • FDA approves first substance use mobile medical application FDA approves first substance use mobile medical application

    Pear Therapeutics' Reset device offers cognitive behavioural therapy. US regulators have approved the first mobile medical application for substance use disorders involving alcohol, cocaine, marijuana and stimulants. ... Pear Therapeutics’ Reset app

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics